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Summary 24 
Aim: Pharmacogenetic studies have identified the presence of the HLA-A*31:01 allele as a predictor 25 
of cutaneous adverse drugs reactions (ADRs) to carbamazepine. This study aimed to ascertain the 26 
preferences of patients and clinicians to inform carbamazepine pharmacogenetic testing services.  27 
Methods: Attributes of importance to people with epilepsy and neurologists were identified through 28 
interviews and from published sources.  Discrete choice experiments (DCEs) were conducted in 82 29 
people with epilepsy and 83 neurologists.  Random-effects logit regression models were used to 30 
determine the importance of the attributes and direction of effect.  31 
Results: In the patient DCE, all attributes (seizure remission, reduction in seizure frequency, memory 32 
problems, skin rash and rare, severe ADRs) were significant. The estimated utility of testing was 33 
greater, at 0.52 (95% CI, 0.19 to 1.00) than not testing at 0.33 (95% CI, -0.07 to 0.81). In the physician 34 
DCE, cost, inclusion in the British National Formulary, coverage, negative predictive value (NPV), and 35 
positive predictive value (PPV) were significant. Marginal rates of substitution indicated that 36 
neurologists were willing to pay £5.87 for a 1 percentage point increase in NPV and £3.99 for a 1 37 
percentage point increase in PPV.  38 
Conclusion: The inclusion of both patients’ and clinicians’ perspectives represents an important 39 
contribution to the understanding of preferences towards pharmacogenetic testing prior to initiating 40 
carbamazepine.  Both groups identified different attributes but had generally consistent 41 
preferences. Patients’ acceptance of a decrease in treatment benefit for a reduced chance of severe 42 
ADRs adds support for the implementation of HLA-A*31:01 testing in routine practice.  43 
 44 
  45 
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What is known about this subject: 46 
• Carbamazepine is associated with severe, immune-mediated adverse drug reactions that may be 47 
predicted, and potentially avoided, by testing for human leukocyte antigen alleles 48 
• There is presently no evidence on the preferences of patients with epilepsy or neurologists 49 
towards pharmacogenetic testing prior to carbamazepine treatment 50 
What this study adds: 51 
• Based on discrete choice experiments, patients were willing to accept a reduced chance of 1-52 
year remission from seizures for a reduction in adverse drug reactions 53 
• Neurologists’ preference for testing was sensitive to the cost of the test, but they were willing to 54 
pay for a modest increase in negative predictive value 55 
  56 
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Introduction 57 
Carbamazepine is used widely as a first-line treatment for focal onset seizures, and has proven 58 
benefits in terms of time to achieving 12-month remission [1,2]. However, it is associated with 59 
common adverse drug reactions (ADRs) [3] and more serious, immune-mediated ADRs, including 60 
cutaneous hypersensitivity reactions such as Drug Induced Hypersensitivity Syndrome (DIHS), 61 
Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The estimated incidence of 62 
SJS-TEN is 1 to 6 per 10,000 persons exposed to carbamazepine with TEN being associated with 63 
mortality of up to 30% [4]. 64 
Pharmacogenetic association studies have identified significant genetic predictors of cutaneous 65 
ADRs associated with carbamazepine.  While rare in European populations, the HLA-B*15:02 allele is 66 
a significant predictor of SJS-TEN in people of Han-Chinese descent [5], and testing significantly 67 
reduces the rate of SJS-TEN [6]. Recommendations from regulators have consequently led to 68 
increased use of HLA-B*15:02 testing of people of Han-Chinese, Thai and other Asian origin in East 69 
Asia. 70 
In European populations, the HLA-A*31:01 allele is a significant predictor of the full spectrum of 71 
carbamazepine-induced hypersensitivity ADRs [7], the risk being 26% in carriers of the allele and 72 
3.8% in non-carriers. Based on the 10% prevalence of mild carbamazepine-induced cutaneous ADRs 73 
(maculopapular exanthema) in people of European descent [1], 39 people would need to be 74 
screened to prevent one carbamazepine-induced ADR [7]. However testing for HLA-A*31:01, which 75 
has a prevalence of 2 to 5% in European populations, has yet to gain mainstream acceptance in 76 
Western countries. As for any new innovation, uptake will be dependent on many factors, not least 77 
patients’ acceptance, and preferences for harm reduction versus benefit maximisation; and 78 
prescribers’ considerations of diagnostic value, clinical utility and cost, among other factors [8]. 79 
Discrete choice experiments (DCEs) are a method for measuring respondents’ stated preference for 80 
healthcare interventions or services [9].  In DCEs, respondents are asked to choose their preferred 81 
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alternative from a set of hypothetical (but realistic) alternatives. The method allows for the 82 
estimation of the relative importance of different aspects of care, assessment of any trade-offs 83 
between these aspects, and of respondents’ total satisfaction (utility) associated with the 84 
intervention or service under consideration [9,10].  DCEs have been used previously to elicit 85 
preferences for antiepileptic drugs (AEDs) [11,12] and for the delivery of pharmacogenetic testing 86 
services [13].  The latter revealed differences in patient and prescriber preferences, with patients 87 
demanding accurate and timely information regarding why testing was necessary and what the test 88 
results meant, while health-care professionals focussed more on the predictive accuracy and waiting 89 
time for a test result [13]. 90 
In the present study, we aimed to ascertain the preferences of patients with epilepsy and 91 
neurologists when considering testing for HLA-A*31:01 prior to prescribing carbamazepine. 92 
Specifically, we estimated patients’ threshold at which the incidence of serious ADR would make 93 
testing worthwhile and neurologists’ willingness to pay for testing. The results of this study may 94 
inform the delivery of pharmacogenetic testing services. 95 
  96 
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Methods  97 
Overview 98 
We identified attributes that patients with epilepsy and neurologists considered important in their 99 
respective consideration of pharmacogenetic testing prior to starting treatment with 100 
carbamazepine.  Levels for each attribute were derived from appropriate sources of clinical 101 
evidence.  Separate DCEs were designed and administered to samples of patients with epilepsy and 102 
neurologists from across the UK.   103 
Participants and administration 104 
Adults aged 18 or over and who self-reported as being diagnosed with epilepsy by a doctor were 105 
eligible.  Participants were not rewarded for their time but were informed of the potential benefits 106 
and risks to them, and had to consent before taking part. Recruitment was facilitated by the UK 107 
charity Epilepsy Action and included advertisements, articles and links using social media, members’ 108 
magazine, e-forums and newsletters, and website home page. An advertisement was placed in the 109 
local press and posters displayed in hospital clinics.  The questionnaire was made available via a link 110 
to an anonymous online service (Snap Surveys, London, UK) between June and October 2013.  Target 111 
sample size was 63 completed DCE responses, based on each main effect level of interest being 112 
represented across the design at least 500 times [14].  Ethical approval was gained from the NHS 113 
National Research Ethics Service (reference 11/NW/0191).       114 
Adult and paediatric neurologists registered in the UK were recruited via the International League 115 
Against Epilepsy and the Association of British Neurologists.  The questionnaire was made available 116 
nationally via an anonymous online service (SurveyMonkey, Palo Alto, CA) between July and October 117 
2012.  The target sample size for the main effects analysis was 47 completed DCE responses [14].  118 
Attribute and level selection 119 
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Attributes for the patient DCE were identified using semi-structured interviews with patients, focus 120 
group with prescribers, and from published data.  Patients (n=56) were recruited from three clinical 121 
sites, and included 33 with established epilepsy (17 females, mean age 38 years) and 23 with a 122 
recent (≤1 year) diagnosis of epilepsy (10 females, mean age 43 years). Forty-one patients were first 123 
asked to list and rank attributes relating to the benefits, side-effects and life-impacts of treatment 124 
for epilepsy.  The second stage of the interviews was designed to explore the framing of risk and the 125 
validity of risk communication.  Fifteen patients participated in cognitive interviews to assess the 126 
face validity of the DCE (presentation of attributes and levels) and were provided with show-cards 127 
depicting risk in pictograms alongside a written explanation of the risk being illustrated.  128 
Interviewers were given notes on how to explain risk.  This exercise was repeated in the focus group 129 
with prescribers (n=8), who were also asked to discuss the frequency and severity at which side-130 
effect became a ‘clinically important adverse event’ that would require a change in treatment.  131 
Prescribers were also asked for feedback on the format of the patient DCE and the presentation of 132 
attributes and levels.  The final DCE of patients co tained 5 attributes to represent remission of 133 
seizures (the highest ranked benefit in the qualitative study), reduction in seizure frequency, 134 
memory problems (the highest ranked side-effect in the qualitative study), skin rash, and rare or 135 
uncommon severe ADRs (associated with carbamazepine) (Table 1).  Appropriate levels for each 136 
category were identified from published clinical data [1,7,15]. 137 
Insert Table 1 here 138 
Attributes for the physician DCE were taken from Payne et al. [13], who identified cost, predictive 139 
accuracy and result turnaround time as being important when considering pharmacogenetic tests; 140 
and from structured individual interviews with neurologists (n=12) recruited from the North West of 141 
England.  Initial interviews involved a discussion of attributes that would be of potential importance 142 
to neurologist when considering a pharmacogenetic test and included: cost, predictive accuracy, 143 
turnaround time to result, coverage of test (severe ADRs only or severe and mild ADRs), inclusion in 144 
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British National Formulary (BNF) [16], method of testing (blood, salivary swab), method of follow-up 145 
and subsequent prescribing, location of testing and method of presentation of results (‘raw data’, 146 
summarised interpretation).   147 
A rating exercise was performed to identify the attributes of greatest importance. Subsequent 148 
interviews with neurologists discussed the presentation of the attributes and identified relevant 149 
levels. As this study targeted UK neurologists, cost was understood to be total cost to the National 150 
Health Service (NHS), rather than cost to the patient or cost for a privately requested test. Although 151 
there is no direct cost to the neurologist or patient, neurologists and physicians in general in the UK 152 
are cognisant of the costs of medical interventions and this characteristic was confirmed by the 153 
identification of the attribute as important in the interviews. Framing of the predictive attributes of 154 
the pharmacogenetic test was discussed. The negative predictive value (NPV) and positive predictive 155 
value (PPV) were understood and favoured by the neurologists compared to alternative methods of 156 
presentation including sensitivity, specificity or ‘risk of ADR following test’.  The final attributes 157 
presented in the DCE were: cost, time to result, inclusion in the BNF, coverage, NPV, and PPV (Table 158 
1). Data from published sources [5,7], together with dis ussion in individual interviews with 159 
neurologists and expert opinion led to identification of a range of plausible attribute levels.   160 
Experimental design 161 
Our qualitative findings did not reveal a common list of attributes that could be used to value both 162 
physician and patient preferences for pharmacogenetic testing services. We therefore conducted 163 
two separate DCEs that contained the most relevant and plausible attributes from both 164 
perspectives.     165 
In clinical practice, patients who test positive for the HLA-A*31:01 allele would be prescribed an 166 
alternative AED, which is likely to have a different benefit and harm profile. To reflect this, the DCE 167 
asked patients to choose between two hypothetical medicines, from which we inferred their 168 
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preference for pharmacogenetic testing. The DCE used a fractional factorial design [18] and folded 169 
into eight binary choices, one of which is presented as an example in Figure 1.  The DCE was 170 
administered as part of a larger survey containing 126 items in total and requiring an estimated 30 171 
minutes for completion  172 
A binary design was selected for the DCE of neurologists in order to include a choice of no testing, 173 
which is aligned with current clinical practice. A fractional factorial design was selected from a design 174 
catalogue to ensure orthogonality [18].  Sixteen choice scenarios were presented to respondents, 175 
following the example shown in Figure 1.   176 
Insert Figure 1 here 177 
Analysis  178 
Random effects logit regression models were used to determine the importance of the attributes 179 
and direction of effect. Marginal rates of substitution (MRS, the rate at which respondents were 180 
willing to give up a unit change in one attribute in exchange for a unit change in another while 181 
maintaining the same level of utility) were calculated using each attribute as the value attribute with 182 
Bootstrapped confidence intervals calculated using 1,000 replications. All analyses were conducted 183 
in STATA version 10 (StataCorp, College Station, TX).  To test the validity of the patient DCE we 184 
identified a potentially dominant choice in which medicine A was superior in all but one attribute 185 
(higher chance of remission, lower risk of memory problems, mild rash and life-threatening ADR; but 186 
a higher frequency of seizures).  We assumed that people who selected the alternative (medicine B) 187 
for this choice did not understand the task, and analysed the DCE with and without these 188 
respondents by comparing the confidence intervals of all the coefficients in the regression to 189 
ascertain if there were statistically significant differences.       190 
Patients’ utility was calculated by weighting the results of the regression against potential outcomes 191 
of treatment with carbamazepine with or without pharmacogenetic testing.  Clinical data [1,7,15] 192 
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were used to model the scenarios of testing (in which carriers of the HLA-A*31:01 allele are 193 
prescribed lamotrigine) and standard care (Table 2).  The probability of test uptake was calculated as 194 
the exponential of the utility for testing divided by the sum of the exponential of the utilities for 195 
testing and not testing.  We further calculated the threshold at which patients would prefer to be 196 
tested, defined when the utility of testing is at least as much as the utility of standard treatment: 197 
−	
() ∗ ∆	
()	≤ ∆


 
where, MRS is the ratio of beta coefficient for a given attribute divided by the beta coefficient for 198 
severe ADRs (sADR), and ∆attribute represents the actual difference in probabilities of occurrence of 199 
attribute-defined events between a testing strategy and standard treatment. The trade-off between 200 
the benefits and harms of interest provides the point of indifference from the patient’s perspective 201 
and therefore represents the threshold at which patients would choose to be tested. 202 
Insert Table 2 here 203 
Scenario analyses 204 
While the base case focused on HLA-A*31:01, a scenario analysis was performed using the 205 
characteristics of testing for HLA-B*15:02. This was based on a meta-analysis of the association with 206 
SJS/TEN [19] and assumed a 10% allele prevalence, consistent with Asian populations [20]. 207 
A further exploratory analysis was conducted by identifying statistically significant subgroups based 208 
on log likelihood ratio tests of base case ‘restricted model’ (all cases) and unrestricted models for 209 
groups of n≥30 and assuming p<0.05 with Bonferroni correction. 210 
For the DCE of neurologists, welfare estimates including total utility and probability of uptake were 211 
calculated for various testing scenarios which represented: a less expensive test, higher PPV and 212 
NPV, and a reduced time to test result. A test which costs £100, takes 4 days for the result, with PPV 213 
26%, NPV 96%, predictive of both severe and mild ADRs but not included in the BNF was selected as 214 
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being representative of current clinical practice associated with HLA-A*31:01 testing. An assessment 215 
of validity using a dominant choice set was not possible in the DCE of neurologists. Pharmacogenetic 216 
testing for HLA-A*31:01 is not currently mandatory and therefore selecting a single scenario where a 217 
test should always or never be selected would not be appropriate in the context of a labelled DCE. 218 
We defined non-traders as respondents always selecting one response (test or no test) and 219 
examined the results of the regression with and without the inclusion of non-traders.    220 
 221 
Results 222 
Patients’ DCE  223 
Ninety-two people with epilepsy started the DCE, of which 82 (89%) completed the survey. 224 
Respondents had a median age of 38 years and 61 (66%) were female (Table 3).  Almost all patients 225 
were taking AEDs (n=85, 99%) and 31 (36%) had experienced changes to their AED treatment in the 226 
previous three months.  Over a third of respondents (n=31, 36%) had previously taken 227 
carbamazepine to treat epilepsy, of which one respondent reported a severe skin reaction requiring 228 
hospitalisation and 10 (19%) had experienced rash of the upper body. 229 
Insert Table 3 here 230 
All 5 attributes were significant and in the expected direction and the overall goodness of fit of the 231 
model was good (Table 4).  Five patients failed to select the dominant choice, however as there were 232 
no statistically significant differences between models by their inclusion or exclusion they were 233 
retained in the base case analysis.  Patients were willing to accept a reduction in the chance of 12-234 
month remission from seizures in exchange for a reduction in adverse events.  Patients were willing 235 
to reduce the chance of remission by: 0.58 percentage points (95% CI, 0.39 to 0.82) for a 1 236 
percentage point reduction in skin rash; 3.2 percentage points (95% CI, 2.32 to 4.44) for a 1 237 
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percentage point reduction in memory problems; and, 1.76 percentage points (95% CI, 1.21 to 2.54) 238 
for a 0.001 percentage point reduction in the risk of a severe ADR. 239 
Insert Table 4 here 240 
Utility model 241 
The estimated utility associated with testing for HLA-A*31:01 was greater, at 0.52 (95% CI, 0.19 to 242 
1.00) than not testing at 0.33 (95% CI, -0.07 to 0.81).  Consequently the choice model estimated the 243 
probability of test uptake at 55% (95% CI, 54 to 57) which would suggest that more patients would 244 
choose to be tested than not. 245 
Patient-defined threshold for testing 246 
The patient-defined threshold for testing for HLA-A*31:01, based on the rate of severe ADRs was 247 
10.20 per 10,000 patients (95% CI, 10.11 to 10.33) which exceeds the actual number of severe ADRs 248 
identified through testing (7.28 per 10,000), suggesting that patients would accept a test.   249 
Scenario analysis 250 
Based on the characteristics of a test for HLA-B*15:02 which, if implemented, is estimated to reduce 251 
the risk of serious ADRs by 6.94 cases per 10,000 patients treated, the probability of patient uptake 252 
is calculated as 61%. Total utility of testing was 0.32 compared with -0.13 for the untested cohort. 253 
The patient-defined threshold for testing is 16.55 severe ADRs per 10,000, implying that testing for 254 
HLA-B*15:02 is also preferred, given that this value exceeds the true rate of serious ADRs of 9.70 per 255 
10,000, if testing were implemented. 256 
Two subgroups qualified for analysis, namely sex and age.  Marginal rates of substitution indicated 257 
that females were more willing than males to trade a reduction in the chance of remission for 258 
reduction in the risk of the severe ADR.  Females were willing to accept a 30.2 percentage point (95% 259 
CI, 19.5 to 52.9) reduction in remission for a 0.1% reduction in the risk of severe ADR, compared with 260 
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males who were only willing to exchange a 4.6 percentage point (95%CI, 0.7 to 11.2) reduction in 261 
remission for the same 0.1% reduction in the risk of severe ADR.  Differences in the rate of exchange 262 
for remission and side-effects (MRS) were not statistically significant for age. 263 
Physicians’ DCE  264 
Eighty-three neurologists completed the questionnaire, the majority (n=69, 83%) were adult 265 
neurologists. Sixty-four (80%) respondents self-rated their knowledge of pharmacogenetic testing as 266 
‘No / Superficial Awareness’, with just 16 (20%) reporting ‘Detailed Awareness’. Fifty-six (67%) 267 
respondents had not requested any pharmacogenetic test in the previous year, while 21 had 268 
requested tests on up to 5 occasions. Forty-three (52%) respondents had reviewed at least one 269 
patient with a cutaneous ADR associated with carbamazepine in the previous year and 69 (83%) 270 
respondents had initiated carbamazepine in at least one patient in the previous month.  271 
Thirteen neurologists were non-traders, defined as respondents who always select A or B (‘test’ or 272 
‘no test’) throughout the experiment, regardless of changes in the profiles. Ten neurologists selected 273 
‘no test’ to all responses and 3 neurologists selected ‘test’ to all responses. As discussed in the 274 
methods, pharmacogenetic testing is not currently mandatory and the decision whether to request a 275 
test will depend on a number of professional factors and personal opinions. During the individual 276 
interviews, a minority of neurologists were opposed to the introduction of pharmacogenetic testing 277 
into routine clinical practice, even when presented with attributes demonstrating a clear clinical 278 
benefit. In order to optimise our assessment of the attributes of a pharmacogenetic test valued by 279 
neurologists, we excluded non-traders from the analysis presented. However, the statistically 280 
significant attributes remained significant when non-traders were included in the model.  The 281 
coefficients of all attributes with the exception of time to test result were significant and in the 282 
expected direction.  Overall goodness of fit of the model was good. The odds that respondents 283 
selected the test decreased by 1% for every £1 increase in the cost of testing. An increase of 1 284 
percentage point in PPV increased the odds of preferring pharmacogenetic testing by 7%; reference 285 
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to HLA-A*31:01 testing in the BNF increased the odds that respondents would test by 58%; and a 286 
test that predicts both severe and mild ADRs decreased the odds of testing by 31% (Table 4). 287 
Marginal rates of substitution for the significant attributes indicated that neurologists were willing to 288 
pay £5.87 for a 1 percentage point increase in NPV and £3.99 for an equivalent increase in PPV. 289 
Respondents were willing to pay £31.29 for the coverage of mild in addition to severe cutaneous 290 
ADRs, and £39.35 for the inclusion of testing advice in BNF (Table 4). 291 
Utility model 292 
The total utility of testing for HLA-A*31:01 is positive at 6.36 (95% CI, 3.74 to 10.22), indicating a 293 
general tendency to request the test (Table 5). Reducing the cost of testing from £100 to £35 294 
increased the probability of requesting the test to 68.1%. A scenario in which the time to test result 295 
is reduced from 4 to 2 days had little influence on the probability of requesting the test, but an 296 
improvement in PPV from 26% to 70%, increased the probability of requesting the test almost 8-fold, 297 
to 88.6%. An improved NPV of 99% compared to the existing 96% increased the probability of 298 
requesting the test to 55.1%.  299 
Insert Table 5 here 300 
Discussion 301 
Using a structured ranking exercise, we found that patients prioritised health outcomes relating to 302 
the benefits of treatment, in terms of seizure freedom and associated adverse events. The results of 303 
the DCE suggested that patients were willing to accept a less effective AED if that treatment had less 304 
risk of harm. They were willing to forego a 1,760 per 100,000 chance of improvement in remission 305 
for each 1 in 100,000 reduction in the risk of a severe ADR.  When patient preferences were 306 
analysed alongside data of actual event rates and characteristics of a test for HLA-A*31:01, the 307 
results indicate that patients would prefer testing and being prescribed lamotrigine (conditional on 308 
test result) to the current standard of care.   The current rate of ADR for patients who have the test 309 
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is 7.28 per 10,000; if this were to increase by an additional 19 (or more) per 10,000, patients would 310 
prefer standard care. 311 
In contrast to patients, neurologists highlighted process-related outcomes. Their preference for 312 
higher NPV might indicate a degree of caution in terms of wanting tests with a reduced likelihood of 313 
false negative results that would require the prescribing of a second choice AED. They were willing 314 
to pay an additional £58.67 per 10 percentage point increase in NPV. Neurologists were willing to 315 
pay an additional £39.35 for a test which was included in the BNF. This attribute captures tests that 316 
are recommended by regulatory agencies or included in clinical guidelines and are more likely to 317 
have high PPV and NPV [22]. A pharmacogenetic test that was less expensive was predictably 318 
preferred, but reduced turnaround time did not significantly influence the probability of requesting 319 
the test.  320 
The study benefitted from having taken a systematic and rigorous approach to identifying attributes 321 
and levels that were both plausible and relevant to each perspective. For the DCE of patients, these 322 
were derived from interviews, with the final selection of attributes and levels piloted in cognitive 323 
interviews and presented in numerical and pictogram format to aid interpretation.  A recent 324 
systematic review found that DCE studies have been notoriously poor at reporting the methodology 325 
supporting the explanation of risk and the validity of risk communication [23].  This study represents 326 
a thorough application of cognitive interviews to support the face validity of the design of the DCE 327 
and the presentation of risk attributes, and associated trading tasks.  A comp rable approach was 328 
taken with neurologists, which included a literature review and structured interviews, consistent 329 
with guidelines for DCE attribute selection [24].  330 
Our inclusion of both patients’ and clinicians’ perspectives represents an important addition to the 331 
emerging literature on preference-elicitation in pharmacogenetics.  The finding that both groups 332 
identified very different attributes but generally consistent preferences is reassuring in the context 333 
of implementing a new health technology. Patients’ acceptance of a decrease in treatment benefit 334 
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for a reduced chance of serious adverse drug reactions – even if that chance is very small – implies 335 
that patients will be satisfied with a prescription for a second choice AED which might not 336 
necessarily be as effective as the first. 337 
Payne et al. [13] evaluated patient and health care professionals’ preferences, using DCE methods, 338 
for pharmacogenetic testing of TPMT prior to treatment with azathioprine.  Their study focused on 339 
service delivery and found that patients valued accurate and timely information about the necessity 340 
of the test and interpretation of the results.  Our patient study differed as it focused on their 341 
preference for different AEDs, accepting that the key consequence of a pharmacogenetic test is the 342 
possibility of being prescribed an alternative medicine with a different safety profile, and potentially 343 
reduced effectiveness. We subsequently modelled the scenario of pharmacogenetic testing using 344 
additional information on the actual benefits of AEDs and test characteristics.  This approach has the 345 
advantage of acknowledging the broader clinical context of testing as opposed to the specific action 346 
of whether or not to test.  Importantly, we have derived the threshold at which patients’ utility will 347 
be maximised through testing prior to taking carbamazepine.   348 
We are aware of two other DCEs of patients with epilepsy. Lloyd et al. [11] used a DCE to elicit the 349 
importance of adverse events compared with seizure control for people with epilepsy and found 350 
that patients preferred AEDs with less severe adverse events, greater control and least cost. This 351 
direction of preferences was the same in our study, however, the amount of remission patients were 352 
willing to forego for a 1% reduction in rash differed: 4.45% seizure control for 1% reduction in risk of 353 
rash compared to a 0.58 percentage point reduction in remission for a 1 percentage point reduction 354 
in rash in our study.  This may be explained by differences in how attributes were presented in the 355 
DCE, in our study we considered a ‘potentially life threatening adverse drug reaction’ that may 356 
influence the strength of preference for other attributes.  Lloyd et al. [11] also included cost, 357 
whereas our study only focused on treatment benefits and harms.   More recently, Manjunath et al. 358 
[12] included attributes for seizure frequency and, among others, ‘short term’ side effects 359 
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(sleepiness, dizziness, headache, nausea, tremor, double or blurred vision, and skin rash) and ‘long 360 
term’ side effects (fatigue, moodiness, confusion or memory problems). Patients with epilepsy 361 
considered seizure reduction to be the top priority when ranked against the reduction or elimination 362 
of side effects. However as with Lloyd et al. [11], there was no consideration of more serious ADRs 363 
which respondents to our DCE considered important. 364 
Our study had some limitations. The survey was conducted online which resulted in a self-selected 365 
sample of patients. This may affect the generalizability of the findings, particularly given that access 366 
to, and use of the internet will be variable among patients with epilepsy. Moreover, the sample 367 
primarily represented prevalent cases with long-standing experience of epilepsy, compared to 368 
incident cases who will be most commonly offered testing. In addition, the severity of epilepsy, 369 
defined as the frequency of seizures, was not recorded in the survey. It is foreseeable that patients 370 
with more severe epilepsy may be willing to trade a greater risk of ADR for an improvement in 371 
seizure control.  Nevertheless, the agreement of our findings with other such studies lends support 372 
to the validity of the results. Common to all DCEs is the balance of comprehensiveness in the 373 
selection of attributes included and ability of respondents to make rational choices. Our DCE of 374 
patients was restricted to the 5 highest ranked attributes each with 2 levels, and only 5 patients did 375 
not select the choice which was marginally dominant and this had no impact on the result. By 376 
contrast, the DCE of physicians was somewhat more extensive with 6 attributes and 16 levels in 377 
total, and 13 respondents were non-traders. Overall, however, we considered the impact of the DCE 378 
designs not to have adversely affected the study conclusions. Finally, the study included a sample of 379 
UK patients and neurologists and the characteristics of these groups as well as the nationally funded 380 
healthcare system where patient care takes place, may limit the generalisability of results. In 381 
particular, the extent to which the results of the assessment of neurologists’ preferences for 382 
pharmacogenetic testing can be extrapolated to other populations may be limited both by different 383 
healthcare systems (for example privatised systems) and different ethnic populations where the risk 384 
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of ADRs associated with carbamazepine may be different. However, importance of the significant 385 
attributes of predictive accuracy (PPV, NPV) will likely translate across all populations.     386 
In conclusion, our analysis of patient preferences indicates that patients value the reduction in risk 387 
of severe ADR which could be achieved by pharmacogenetic testing prior to prescribing 388 
carbamazepine.  The DCE of neurologists would suggest that the most effective method of ensuring 389 
that current pharmacogenetic tests are used more widely would be for the cost of testing to reduce. 390 
Reassuringly, testing for HLA-A*31:01 is cost-effective [25] meaning that turnaround time to result 391 
will likely become important given there is often a clinical urgency and patient expectation for 392 
treatment of uncontrolled seizures. 393 
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Figure 1:  Example of binary choice DCE questions 
Physician DCE Patient DCE  
 
Question: “You have decided to prescribe carbamazepine for your patient. 
You may either select the following pharmacogenetic test prior to the 
prescription, or select not to test and proceed with the prescription 
blindly” 
 
Cost  £35 
Days to result  2 
Positive predictive value (PPV)  2% 
Negative predictive value (NPV)  70% 
Coverage  Serious ADRs ONLY 
Inclusion in British National Formulary (BNF)  Yes 
 
 I WOULD select the test prior to the prescription of 
carbamazepine 
 I WOULD NOT select the test and proceed with the prescription of 
carbamazepine blindly 
 
 
 
 
Question: “Which medication would you prefer?”   
 
 
 MEDICATION A MEDICATION B 
Stop Seizures 
 
One year after  
starting this medication 
 
5 in 10 people 
seizures stop 
 
3 in 10 people 
seizures stop 
Fewer Seizures 
 
One year after  
starting this medication 
 
3 in 10 people 
experience fewer seizures 
 
1 in 10 people 
experience fewer seizures 
Mild skin rash  
 
A blotchy, itchy red rash on 
your upper body 
 
 
 
 
 
1 in 100 people  
experience a mild skin rash 
 
 
 
 
 
26 in 100 people  
experience a mild skin rash 
Memory Problems 
 
These are frequent and  
affect activities of daily life 
 
 
 
 
 
1 in 100 people 
experience memory problems 
 
 
 
 
 
7 in 100 people  
experience memory problems  
Potentially life-
threatening reaction 
 
Severe skin reaction that 
may cause death   
 UNCOMMON 
More than 1 in 1000 people  
experience a life-threatening 
reaction 
RARE 
More than 1 in 10,000 people 
experience a life-threatening 
reaction  
Which medication 
would you prefer to 
take? 
  
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Table 1:  Attributes and levels of the discrete choice experiments 
Attribute  Description  Levels (code) Rationale 
Physicians’ DCE    
Cost of Test  The total cost of the pharmacogenetic 
test in Pounds Sterling.  
35 (0) 
100 (1) 
200 (2) 
Cost attribute ranked highly by neurologists. 
Realistic levels based on expert opinion (M 
Pirmohamed).  
Time to Result The total time from initially requesting 
the pharmacogenetic test to receipt of 
result.  
2 (0) 
4 (1) 
7 (2) 
Time attribute ranked highly by neurologists. 
Realistic levels based on expert opinion (M 
Pirmohamed).  
Positive Predictive Value 
(PPV) 
The probability of experiencing the ADR 
if a positive result is identified on the 
pharmacogenetic test: the ‘true 
positives’. 
2 (0) 
35 (1) 
70 (2) 
PPV attribute ranked highly by neurologists. Range 
of PPV values informed by literature review [5-7]  
Negative Predictive 
Value (NPV) 
The probability of not experiencing the 
ADR if a negative result is identified on 
the pharmacogenetic test: the ‘true 
negatives’.  
70 (0) 
85 (1) 
99 (2) 
 
NPV attribute ranked highly by neurologists. Range 
of NPV values informed by literature review [5-7] 
Coverage of Test The ability of the pharmacogenetic test 
to predict severe ADRs only, or mild in 
addition to severe ADRs.  
Severe Hypersensitivity 
Adverse Drug Reactions (0) 
Severe AND Mild 
Hypersensitivity Adverse 
Drug Reactions (1) 
Parameter informed by the attributes of current 
alleles: HLA-A*31:01 is associated with severe and 
mild ADRs [7], HLA-B*15:02 is associated with 
severe ADRs only [5]  
British National 
Formulary (BNF) 
The inclusion or exclusion of the 
pharmacogenetic test in the drug 
information detailed under 
carbamazepine.  
Test NOT INCLUDED in the 
BNF (0) 
Test INCLUDED in the BNF 
(1) 
Regulatory approval and inclusion in clinical 
guidelines ranked highly by neurologists. Inclusion 
in the British National Formulary [16] was included 
in the DCE as a pragmatic marker of regulatory 
approval and clinical availability.   
Patients’ DCE  
Seizures Stop The probability of patients achieving 1-
year remission from seizures with AED 
5 in 10 people (0.5) 
3 in 10 people (0.3) 
Primary outcome of AED studies is 12 month 
remission.  Levels based on published clinical trial 
data [1]. 
Fewer seizures The probability of patients experiencing 3 in 10 people (0.3) Seizure reduction was the highest ranked outcome 
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fewer seizures after 1-year with AED 1 in 10 people (0.1) by patients.  Levels based on clinical trial data [1]. 
Mild skin rash The probability of patients experiencing 
a mild adverse drug reaction but which 
is sufficient to warrant change in AED 
1 in 100 people (0.01) 
26 in 100 people (0.26) 
HLA-A*31:01 allele is associated with mild 
hypersensitivity reaction with patients exposed to 
carbamazepine.  Levels based on published data 
[1,7]. 
Memory problems The probability of patients experiencing 
memory problems which are sufficient 
to warrant change in AED 
1 in 100 people (0.01) 
7 in 100 people (0.07) 
Adults with established epilepsy and prescribing 
clinicians were most concerned about memory 
problems in ranking exercises.  Levels based on 
published clinical trial data [1]. 
Potentially life-
threatening reaction 
The probability of patients experiencing 
a rare but severe skin reaction, 
described as hot, painful patches on the 
skin that can blister and risks death.   
RARE: More than 1 in 10 000 
people (0.0001) 
UNCOMMON: More than 1 
in 1000 people (0.001) 
HLA-A*31:01 allele is associated with Drug Induced 
Hypersensitivity Syndrome (DIHS), Stevens-
Johnson Syndrome (SJS) and Toxic Epidermal 
Necrolysis (TEN) with patients exposed to 
carbamazepine.  Levels based on published data on 
allele associations [7] and SmPC for carbamazepine 
[17]. 
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Table 2: Values of regression variables used to estimate utility, probability of test uptake and 
maximally tolerated rate of severe ADR for patients to prefer testing. Data are taken from source, or 
derived according to standard epidemiological calculations. 
 
Expected probabilities conditional on 
AED and HLA-A*31:01 test result 
Testing Strategy 
Reference 
Attributes CBZ / -ve CBZ / +ve LTG / +ve Test
 
No test 
Remission 36.000 36.000 29.000 35.8189 36.0000 [1] 
Fewer 
seizures 
17.370 17.370 21.430 17.4751 17.3700 [1] 
Memory 
problems 
3.1746 3.1746 2.6455 3.1609 3.1746 [1] 
Skin rash  7.000 34.000 4.000 6.9224 7.6986 [1,7] 
Severe ADR 0.0738 1.0895 0.0354 0.0728 0.1001 [7,15,17] 
All data are reported as number of events per 100 patients. 
Abbreviations: AED is anti-epileptic drug; CBZ is carbamazepine; LTG is lamotrigine; ADR is adverse 
drug reaction 
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Table 3: Patient characteristics 
Patients’ characteristics n % 
   
Age: median (range) 38 (18-72) 
Female 61 66.3 
Time since diagnosis:   
Less than 4 months 1 1.1 
4-12 months 3 3.3 
1-5 years 14 15.4 
6-10 years 12 13.2 
More than 10 years 61 67.0 
Seizure type:   
Focal 27 31.4 
Complex focal 40 46.5 
Absences, tonic, atonic 45 52.3 
Tonic clonic 56 65.1 
Time since last seizure:    
Less than a week 38 44.2 
Less than a month 16 18.6 
Less than 6 months 14 16.3 
Less than a year 2 2.3 
A year or over 16 18.6 
Seizure frequency compared to 1 year ago: 
More often 19 22.1 
Less often  26 30.2 
About the same 41 47.7 
Prescribed AED in past 3-months 85 98.8 
Changes to AED in past 3-months: 
No change 54 63.5 
Increased/decreased 25 29.4 
Change of drug 9 10.6 
Additional drug 12 14.1 
Fewer drugs 2 2.4 
Stopped altogether 1 1.2 
Reason for changes:   
Lack of seizure control  30 90.9 
Unpleasant side effects 14 42.4 
Remission  1 3.0 
Morisky non-adherence [21] 16 50.0 
Experience of taking CBZ 31 36.5 
Experience of adverse events: 
Change or stop due to memory problems 8 24.2 
CBZ skin rash 10 18.5 
CBZ severe ADR (requiring hospital 
treatment) 1 1.9 
Living alone 13 15.9 
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In employment, education, or looking after 
home 49 60.5 
Ethnicity:    
White 74 90.2 
Black / African / Caribbean / Black British 3 3.7 
Asian / Asian British 1 1.2 
Mixed / Multiple ethnic groups 2 2.4 
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Table 4: Random effects logit regression model and marginal rates of substitution 
DCE of patients 
Attribute Coefficient (95% CI) 
Odds 
ratio 
Remission (95% CI) 
Remission 0.037 
(95% CI 0.032 to 0.054 
1.04 1.00 
Fewer seizures 0.011 
(95% CI 0.003 to 0.024) 
1.01 0.29 
(95% CI 0.07 to 0.58) 
Memory  -0.119 
(95%CI -0.182 to -0.104) 
0.89 -3.22 
(95% -4.54 to -2.35) 
Skin rash -0.021 
(95% CI -0.034 to -0.016) 
0.98 -0.58 
(95% CI -0.84 to -0.38) 
Severe ADR -6.490 
(95% CI -10.295 to -5.467) 
0.00 -175.83 
(95% CI -253.30 to -121.42) 
Constant 0.147 
(95% CI -0.022 to 0.392) 
1.16  
Pseudo-R
2
 = 0.2118; Wald χ
2
 140.34; Log likelihood = -382.74; p=0.00  
DCE of neurologists 
Attribute Coefficient (95% CI) 
Odds 
ratio 
Willingness to pay (95% CI) 
Cost  -0.012 
(95% CI -0.016 to -0.010) 
0.99 
- 
- 
Time to Result 0.027 
(95% CI -0.077 to 0.131) 
1.03 
- 
- 
PPV 0.047 
(95% CI 0.042 to 0.061) 
1.05 
3.99 
(95% CI 3.00 to 5.37) 
NPV 0.068 
(95% CI 0.056 to 0.096) 
1.07 
5.87 
(95% CI 4.04 to 8.46) 
Coverage of 
Test 
-0.365 
(95% CI -0.774 to -0.095) 
0.69 
-31.29 
(95% CI -60.06 to -7.20) 
Included in 
BNF 
0.459 
(95% CI 0.140 to 0.865) 
1.58 
39.35 
(95% CI 10.97 to 71.05) 
Constant -7.120 
(95% -9.879 to -5.824) 
  
Pseudo-R
2
 value 0.2294; Wald χ
2
 199.74; Log likelihood = -529.66; p<0.001 
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Table 5: Results of scenario analysis of varying attribute levels within plausible ranges on the total 
utility and probability of test uptake  
Parameter Attribute and levels Utility Probability of 
uptake 
Base case Cost: £100 
Time to result: 4 Days 
PPV: 26% 
NPV: 96% 
Coverage of test: Severe 
and mild 
Included in BNF: No 
6.3584 
(95% CI: 3.7391 – 10.2210) 
49.9% 
Reduced cost  Cost: £35 7.117 
(95% CI: 4.8012 – 10.8525) 
68.1% 
Reduced time to 
result 
Time to result: 2 Days 6.3046 
(95% CI: 3.8939 – 9.9629) 
48.6% 
Improved PPV PPV: 70% 8.4055 
(95% CI: 5.5658 – 12.8900) 
88.6% 
Improved NPV NPV: 99% 6.5639 
(95% CI: 3.9072 – 10.5111)  
55.1% 
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